A picture containing clipart

Description generated with very high confidence

***Federation of International Lacrosse Anti-Doping policies, procedures, and practices***

*Approved July 7, 2018 FIL Board of Directors*

FIL is committed to full compliance with all provisions of the WADA Code and the principles of clean sport and has approved the following policies, procedures and practices to guide it in managing its Anti-Doping Program.

**FIL Anti-Doping Procedures**:

1.0. **Filing of Doping Control Forms**. FIL is committed to full compliance with all provisions of the WADA Code and the principles of clean sport. FIL requires all Doping Control Forms to be entered into ADAMs within 15 days of sample collection. The FIL Anti-Doping Administrator or FIL management if the FIL ADA is unavailable will enter the DCF forms into ADAMs.

2.0. **Therapeutic Use Exemptions**. FIL shall promptly report all decisions of its Therapeutic Use Exemption Committee through ADAMs which includes the TUE application form and the relevant clinical information (translated in English or French) as per the relevant requirements contained in the International Standard for Therapeutic Use Exemptions (ISTUE). The FIL ADA supported by the FIL management team shall be responsible for fulfilling this procedure.

3.0. **Risk Assessment**. FIL shall annually prepare a risk assessment detailing an analysis of the risks of doping in the sport of lacrosse. The risk assessment shall be completed by the FIL Management with the assistance of the FIL Technical Director and the FIL ADA.

4.0. **Testing and Investigations**. The FIL Technical Director shall identify and report the name of the manufacturer that the relevant collection authorities will be using for sample collection for all FIL World Events and shall ensure that the sample collection equipment meets the requirements of the ISTI Article 6.3.4.

5.0. **Results Management.** All FIL Members as a condition of membership are required to comply with all provisions of the WADA Code and adopt Anti-Doping Rules in line with the Code as prescribed in Article 20.3.2 and shall be subject to periodic review to ensure that the policies, rules, and programs of the National Federations are in compliance with the Code. FIL shall inform NGB’s of the policy and requirement, ask NGB’s annually for confirmation that they are complying with the requirement and review links and documentation provided by NGB’s for compliance, and undertake a process to ensure compliance through direct NGB review.

6.0. **Results Management**. When there is reasonable cause to suspect that an anti-doping rule violation may have been committed, the fil shall notify WADA that it is starting an investigation into the matter in accordance with Code Article 7.6 or Code Article 7.7, as applicable. Thereafter FIL shall keep WADA updated on the status and findings of the investigation upon request.”

7.0. **Data Privacy #1**: FIL shall ensure that adequate information is provided to the participant or person to whom the personal information relates as per the International Standard for the Protection of Privacy and Personal Information (ISPPPI) Articles 6.2 and 7 when data is collected or retained in the execution of FIL Anti-Doping protocols or programming. Athletes shall be afforded the opportunity to provide informed consent via the FIL ISPPPI data collection consent form.

8.0. **Data Privacy #6**: When entering into formal agreements with service providers FIL shall put contractual controls in place in order to protect the confidentiality and privacy of the personal data shared and to ensure that the personal data is only processed for and on behalf of the FIL as required by Article 9.4 of the ISPPPI.

9.0. **FIL Anti-Doping Statistics**. In accordance with Code Article 14.4, FIL shall publish, as a minimum, an annual statistical report of its Doping Control activities, and shall provide a copy to WADA.

10.0. **Registered Testing Pool**. As per International Standard for Testing and Investigations (ISTI) Article 4.8.7, FIL will review periodically (but no less than quarterly) the list of athletes in its Registered Testing Pool (RTP) to ensure that each listed athlete continues to meet the relevant criteria. The FIL ADA will conduct this review.

11.0**. Registered Testing Pool.** FIL shall notify RTP athletes of their inclusion in a Registered Testing Pool of their rights, responsibilities and consequences via the FIL Notice of Athlete inclusion in RTP document. The FIL ADA and management shall coordinate the notification of RTP athletes.

12.0. **Registered Testing Pool**. As per International Standard for Testing and Investigations (ISTI) Article I.2.4, FIL shall provide written notice to athletes who are no longer included in FIL’s Registered Testing Pool (RTP). The FIL ADA and management shall coordinate the notification of athletes.

13.0. **Whereabouts Pool**. FIL shall, as per International Standard for Testing and Investigations (ISTI) Annex I.2.2, require the coordination of the provision of whereabouts with other Anti-Doping Organizations (ADOs) who have jurisdiction over athletes in its Registered Testing Pool (RTP) or another whereabouts pool.

FIL shall annually through its Technical Director coordinate with its National Federations and other ADO’s who may have FIL athletes in their Whereabouts pool via written communication and will determine jurisdiction of said athletes and execute sharing agreements with those NADO’s.

14.0. **Sample Collection**. As per International Standard for Testing and Investigations (ISTI) Article 6.3.3, the FIL shall establish criteria for who may be authorized to be present during the Sample Collection Session (in addition to the Sample Collection Personnel). FIL has established the following guidelines and criteria for who may be authorized to be present during the sample collection session:

a) An Athlete’s is entitled to be accompanied by a representative and/or interpreter during the Sample Collection Session, except when the Athlete is passing a urine Sample;

b) A Minor Athlete’s entitlement (as provided for in Annex C – Modifications for Athletes who are Minors), and the witnessing DCO/Chaperone’s entitlement to have a representative observe the witnessing DCO/Chaperone when the Minor Athlete is passing a urine Sample, but without the representative directly observing the passing of the Sample unless requested to do so by the Minor Athlete;

c) an Athlete with an impairment shall be entitled to be accompanied by a representative as provided for in Annex B Modifications for Athletes with Impairments;

d) A WADA observer where applicable under the Independent Observer Program. The WADA observer shall not directly observe the passing of a urine Sample.

The FIL Technical Director or his designee shall ensure Doping Control Officers (DCOs) are provided with this information. If FIL is not the Sample Collection Authority, the FIL Technical Director shall ensure the SCA is meeting this requirement.”

15.0. **Sample Collection**. The FIL Technical Director shall inform the Sample Collection personnel (SCP) in advance of any testing mission when and if any minor may be tested at a sample collection session in accordance with Section 10.3 of the Urine Sample Collection Guidelines and ensure that the necessary parental consent is in place.

16.0. **Results Management**. As per Code Article 20.3.2, FIL shall ensure that all National Federations have implemented policies, programs and rules that are compliant with the Code. The Technical Director shall ensure that when results management is delegated to the NF’s that impartial disciplinary panels are in place.

17.0. **Athlete Correspondence**. FIL shall ensure that WADA and the applicable ADO are copied on all relevant correspondence to the athlete are required by International Standard for Testing and Investigations (ISTI).”

18.0**. Athlete Whereabouts**. FIL will by practice notify the affected athlete within 14 days of an apparent whereabouts failure.